Decheng Capital

Decheng Capital is a leading venture capital firm that provides capital to early and growth stage life science companies in China. They are a team of investment professionals with complementary expertise, a long history of working together and a shared dedication to building highly successful companies that span the full spectrum of the life sciences industry. Their domain knowledge, access to innovative technologies and ability to bring proven Western products to China make them the preferred partner for entrepreneurs, domestic and multinational companies, government agencies and investors. Decheng Capital is poised to capitalize on a historic opportunity in China’s rapidly developing life sciences industry and to deliver superior returns for their investors.
SY

Susan Y. Chen

Associate

PC

Peter Colabuono

Principal

Min Cui

Founder and MD

XC

Xiangmin Cui

Founder, Founding Partner, Managing Partner and MD

AL

Aaron Li

VP

YL

Yang Lu

VP

Dayton Misfeldt

Partner

Nick Pliam

Partner

Victor Tong

Partner

Tony Tong

Principal

Qiang Xu

Partner

YK

Y. Katherine Xu

Partner

WX

Wei Xu

Partner

Dan Zabrowski

Venture Partner

70 past transactions

Nanjing Bioheng Biotech Co., Ltd., a clinical biopharmaceutical and a biotechnology company, develops immunotherapy and gene therapy for treating cancer and various diseases. The company offers precision and scarless gene editing and CART therapy. It also develops a production platform for manufacturing plasmid, virus, and cells. The company was founded in 2017 and is based in Nanjing, China.

Apexigen

Series B in 2018
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for the treatment of cancer. The company develops a pipeline of therapies and product candidates, including APX005M and APX201 for immuno-oncology, APX003/BD0801 and TRK-950 for oncology, APX001/SSS07 for inflammation, and APX003/TK001 for ocular diseases. It also develops APXiMAB platform, which enables discovery of antibodies for novel immune system targets. The company was founded in 2010 and is based in San Carlos, California.
EpimAb Biotherapeutics, Inc operates as a biopharmaceutical research and development company develops novel bispecific antibody therapeutics for immuno-oncology and other areas of patients. Its Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform generates bispecific molecules with antibody-like properties. The company is based in Shanghai, China.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Cellares

Series B in 2021
Cellares Corporation develops cell therapy for the treatment of cancer. The company develops solution to overcome limitation of manufacturing to make cell therapies for patients. Cellares Corporation was founded in 2019 and is based in South San Francisco, California.

GeneWEAVE

Series B in 2014
GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation.
Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

VelosBio, Inc.

Series A in 2018
VelosBio, Inc., a biopharmaceutical company, develops novel antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company develops cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its portfolio includes VLS-101, a ROR1-directed antibody-drug conjugate for patients with hematologic and solid tumor malignancies. The company was incorporated in 2017 and is headquartered in San Diego, California. As of December 18, 2020, VelosBio, Inc. operates as a subsidiary of Merck & Co., Inc.

Nalu Medical

Venture Round in 2022
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Cue Health Inc.

Series C in 2020
Cue is a revolutionary device for tracking health information at the molecular level. For the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Encodia, Inc.

Series C in 2020
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.

PackGene Biotech, LLC

Series C in 2021
PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Mammoth Biosciences

Series D in 2021
Mammoth Biosciences, Inc., a biotechnology company, develops clustered regularly interspaced short palindromic repeats (CRISPR0 solutions. It offers DETECTRTM that searches for the presence of specific nucleic acids in a sample that are indicative of disease, providing actionable clinical information for various diagnostic applications, such as single nucleotide polymorphisms (SNP), bacterial infections, cancer screening and profiling, antimicrobial resistance, and viral infections. The company also provides CRISPR-Cas systems to edit the genome for therapeutic applications, including immuno-oncology, autoimmune diseases, and liver diseases. Its solutions are used in healthcare, agriculture, environmental monitoring, biodefense, and other applications. Mammoth Biosciences, Inc. was formerly known as Apheleia Diagnostics, Inc. The company was founded in 2017 and is based in South San Francisco, California.

ImmPACT Bio USA

Series B in 2022
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Adela

Series A in 2021
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Watchmaker Genomics

Series A in 2022
Watchmaker Genomics, Inc. operates as a biotechnology company that engages in research and development of genomes. It offers protein engineering with enzyme manufacturing. Its platform offers solutions to improve genomic experiment, assay and workflow, and scalable supply-chain solutions. Watchmaker Genomics, Inc. was formerly known as Alpha Catalyst Genomics, Inc. and changed its name to Watchmaker Genomics, Inc. in July 2019. The company was incorporated in 2018 and is based in Boulder, Colorado.

AnHeart Therapeutics

Series A in 2019
AnHeart Therapeutics is a developer of innovative pharmaceutical products. The company is focused on acquiring, developing and commercializing innovative pharmaceutical products that improve human health and quality of life. It's main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.

Cirina

Series A in 2016
Cirina is developing innovative blood-plasma tests to detect deadly diseases at their earliest stages when curative treatments are most viable. The company is driven by the passion and life-long work of Co-founder and plasma nucleic acid pioneer, Dennis Lo, the first scientist to discover the presence of fetal DNA in a pregnant mother’s blood-plasma. Headquartered in South San Francisco, Calif., Cirina is currently actively recruiting top scientific and business talent to join its quest to detect devastating diseases like cancer at their earliest stages and empower people to take action. For more information, please visit http://cirinalabs.com.

Equillium

Post in 2021
Equillium Inc is a biotechnology company that develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with an unmet medical need. Its primary product candidate is EQ001, which is a clinical-stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis.

Aadi Bioscience

Series A in 2017
Aadi Bioscience, Inc., a clinical stage biopharmaceutical company, develops mTOR inhibitor for patients in oncology and cardiovascular diseases. It offers ABI-009, a clinical phase mTOR inhibitor for the treatment of therapeutic areas, including oncology, cardiovascular, and metabolic related diseases. Aadi Bioscience, Inc. was formerly known as AADi LLC. The company was founded in 2011 and is based in Pacific Palisades, California.

Neurelis, Inc.

Series D in 2021
Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance the therapeutic benefit and patient care. The company was incorporated in 2007 and is based in Encinitas, California.

LevitasBio

Series B in 2021
Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Our disruptive technology overcomes the current technological limitation of cellular analysis by providing label free, simple, and universal methods of analysis. We are developing our platform across a wide range of cellular applications, including therapeutic, diagnostic, and research applications, which will enable a wide range of novel research and precision health.

AccuraGen Holdings

Series B in 2016
We have developed a high-sensitivity next-generation sequencing-based system for the the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

Shape Therapeutics

Series B in 2021
Shape Therapeutics, Inc., a biotechnology company, provides RNA-editing gene therapy for neurodegenerative disorders, oncology, metabolic, and rare genetic diseases. It offers RNAfix technology that allows editing of RNA using natural human cellular machinery, limiting the risk associated with immunogenicity, cellular toxicity, and off-target DNA editing. Shape Therapeutics, Inc. was founded in 2018 and is based in Seattle, Washington.

Mirvie

Series B in 2022
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.

Everest Medicines Limited

Series C in 2020
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.

Cue Health Inc.

Series C in 2020
Cue is a revolutionary device for tracking health information at the molecular level. For the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

ARMO BioSciences, Inc.

Series C in 2017
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Shape Therapeutics

Series B in 2021
Shape Therapeutics, Inc., a biotechnology company, provides RNA-editing gene therapy for neurodegenerative disorders, oncology, metabolic, and rare genetic diseases. It offers RNAfix technology that allows editing of RNA using natural human cellular machinery, limiting the risk associated with immunogenicity, cellular toxicity, and off-target DNA editing. Shape Therapeutics, Inc. was founded in 2018 and is based in Seattle, Washington.

Baoyuan Biomedical

Series A in 2019
Baoyuan Biomedical is a clinical stage company focused on acquiring, developing and commercializing innovative drugs that improve human health and quality of life, and is committed to innovative drug development that does not meet clinical needs. Its main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.

PackGene Biotech, LLC

Series B in 2020
PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.

ReadCoor, Inc.

Series A in 2016
ReadCoor, Inc. develops and commercializes a panomic spatial sequencing platform for researchers, clinicians, pharmaceutical and diagnostics companies, and patients worldwide. It offers FISSEQ, a platform that enables integration of high throughput sequencing, morphometric analysis, cellular location, and three-dimensional spatial imaging. The company’s platform also enables researchers to perform RNA-Seq while preserving sample morphology and simultaneously providing cellular location and spatial image data. ReadCoor, Inc. was incorporated in 2016 and is based in Cambridge, Massachusetts. As of October 13, 2020, ReadCoor, Inc. operates as a subsidiary of 10x Genomics, Inc.
Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

GRIT Biotechnology

Series A in 2021
GRIT Biotechnology is engaged in research and development of tumor infiltration lymphocytes immunotherapy for curing solid tumors. The company is based in Shanghai, China.
Lynk Pharmaceuticals (Hangzhou) Co., Ltd. is engaged in the development of small molecule drugs for tumors and autoimmune diseases through new drug research, sales, patent authorization and patent transfer. The firm was founded in 2017 and is headquartered in China.

GRIT Biotechnology

Series A in 2020
GRIT Biotechnology is engaged in research and development of tumor infiltration lymphocytes immunotherapy for curing solid tumors. The company is based in Shanghai, China.

Cue Health Inc.

Private Equity Round in 2021
Cue is a revolutionary device for tracking health information at the molecular level. For the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Apexigen

Series C in 2020
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for the treatment of cancer. The company develops a pipeline of therapies and product candidates, including APX005M and APX201 for immuno-oncology, APX003/BD0801 and TRK-950 for oncology, APX001/SSS07 for inflammation, and APX003/TK001 for ocular diseases. It also develops APXiMAB platform, which enables discovery of antibodies for novel immune system targets. The company was founded in 2010 and is based in San Carlos, California.

Omniome

Series C in 2020
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. Founded in 2013, the company is headquartered in San Diego, California, United States.

KeChow Pharma

Series C in 2019
Shanghai Kechow Pharma, Inc., a biopharmaceutical company that focuses on novel drug discovery. It discovers targeted small molecule drugs over existing therapies and co-develops the drugs with partners. The company was founded in 2014 and is based in Shanghai, China.

Luckin Coffee

Series B in 2018
Luckin coffee, a representative of China's new retail coffee, is committed to becoming a leading high-quality coffee brand and professional coffee service provider in the country. Luckin coffee, with preferred raw materials, exquisite coffee technology, innovative business models and leading mobile internet technologies, is striving to bring a higher quality coffee consumer experience to consumers and promote the popularization and development of coffee culture in China.

Ark Biosciences Inc.

Series C in 2021
Ark Biosciences Inc., a biopharmaceutical company, discovers and develops therapeutics to address unmet medical need in the areas of respiratory viral infection and viral hepatitis for worldwide markets. Its products include AK0701 for Chronic obstructive pulmonary disease (COPD), AK0529 for Respiratory syncytial virus (RSV), AK0612 for Influenza, and AK0705 and AK0706 for Hepatitis B. The company was founded in 2013 and is based in Shanghai, China.

SentreHEART

Series D in 2016
SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada.

Omniome

Series B in 2018
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. Founded in 2013, the company is headquartered in San Diego, California, United States.

Terns Pharmaceuticals

Series B in 2018
Terns Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops molecularly targeted, oral, small-molecule drugs to treat cancer and liver diseases. Its products includes TERN-101, a potent non-bile acid farnesoid X receptor agonist and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company was founded in 2017 and is based in Foster City, California with additional offices in Shanghai, China.

GeneWEAVE

Series A in 2012
GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation.

Sema4

Series C in 2020
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Hummingbird Bioscience

Series A in 2019
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

IMPACT Therapeutics, Inc.

Series C in 2018
IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more than four decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology.

Polares Medical S.A.

Series A in 2018
Polares Medical S.A. manufactures and markets medical device to reduce or eliminate mitral valve regurgitation. The company is based in Ecublens, Switzerland, with additional office in Palo Alto, California.
Nanjing Bioheng Biotech Co., Ltd., a clinical biopharmaceutical and a biotechnology company, develops immunotherapy and gene therapy for treating cancer and various diseases. The company offers precision and scarless gene editing and CART therapy. It also develops a production platform for manufacturing plasmid, virus, and cells. The company was founded in 2017 and is based in Nanjing, China.

GenapSys, Inc.

Series B in 2013
GenapSys is actively looking to partner with local health agencies and researchers to arm researchers with access to the insight afforded by sequencing. With its sequencing technology, the company aims to help support the control and limit the spread of current and future outbreaks. The device can run off of a standard power source and is small enough to fit in the back of a truck or be deployed at hospitals, airports, and public transportation hubs for quick results on virus samples. It was founded in 2010 and headquartered in Redwood City, California.

LevitasBio

Venture Round in 2017
Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Our disruptive technology overcomes the current technological limitation of cellular analysis by providing label free, simple, and universal methods of analysis. We are developing our platform across a wide range of cellular applications, including therapeutic, diagnostic, and research applications, which will enable a wide range of novel research and precision health.

Mynosys Cellular Devices

Venture Round in 2019
Mynosys Cellular Devices is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enable procedural excellence

Mindstrong Inc.

Series B in 2018
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.

ReadCoor, Inc.

Series B in 2020
ReadCoor, Inc. develops and commercializes a panomic spatial sequencing platform for researchers, clinicians, pharmaceutical and diagnostics companies, and patients worldwide. It offers FISSEQ, a platform that enables integration of high throughput sequencing, morphometric analysis, cellular location, and three-dimensional spatial imaging. The company’s platform also enables researchers to perform RNA-Seq while preserving sample morphology and simultaneously providing cellular location and spatial image data. ReadCoor, Inc. was incorporated in 2016 and is based in Cambridge, Massachusetts. As of October 13, 2020, ReadCoor, Inc. operates as a subsidiary of 10x Genomics, Inc.

GenapSys, Inc.

Series A in 2013
GenapSys is actively looking to partner with local health agencies and researchers to arm researchers with access to the insight afforded by sequencing. With its sequencing technology, the company aims to help support the control and limit the spread of current and future outbreaks. The device can run off of a standard power source and is small enough to fit in the back of a truck or be deployed at hospitals, airports, and public transportation hubs for quick results on virus samples. It was founded in 2010 and headquartered in Redwood City, California.
EpimAb Biotherapeutics, Inc operates as a biopharmaceutical research and development company develops novel bispecific antibody therapeutics for immuno-oncology and other areas of patients. Its Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform generates bispecific molecules with antibody-like properties. The company is based in Shanghai, China.

Arcus Biosciences, Inc.

Series C in 2017
Arcus Biosciences is biotech company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub.

Mammoth Biosciences

Series B in 2020
Mammoth Biosciences, Inc., a biotechnology company, develops clustered regularly interspaced short palindromic repeats (CRISPR0 solutions. It offers DETECTRTM that searches for the presence of specific nucleic acids in a sample that are indicative of disease, providing actionable clinical information for various diagnostic applications, such as single nucleotide polymorphisms (SNP), bacterial infections, cancer screening and profiling, antimicrobial resistance, and viral infections. The company also provides CRISPR-Cas systems to edit the genome for therapeutic applications, including immuno-oncology, autoimmune diseases, and liver diseases. Its solutions are used in healthcare, agriculture, environmental monitoring, biodefense, and other applications. Mammoth Biosciences, Inc. was formerly known as Apheleia Diagnostics, Inc. The company was founded in 2017 and is based in South San Francisco, California.

Sema4

Series B in 2019
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Polares Medical S.A.

Series B in 2020
Polares Medical S.A. manufactures and markets medical device to reduce or eliminate mitral valve regurgitation. The company is based in Ecublens, Switzerland, with additional office in Palo Alto, California.